Table 4: Recent randomised controlled trials of weight loss therapies with 6-month followup.

DrugNo. subjectsOutcomesSerious adverse eventsReference
Absolute weight loss (kg) (95% CI)≥5% weight loss≥10% weight lossChange in WC (cm)

Bupropion (400 mg) plus NaltrexonePlacebo-85 15%2% Nausea: 3.5% P, 28.1% BN16, 39.7% BN32, 41% BN48[22]
N 48 mg-56 B-60 10%2%
BN16 mg-64 26%7%
52%, 17%, ,
BN 32 mg-63 51%, 19%, ,
BN 48 mg-61 39%, 15%, ,

Bupropion (120 mg/360 mg) + Zonisamide (360 mg/360 mg)729 (total)1.4 P15% P4% PNANA[97]
3.2 Z120
Z360
27% Z120 Z3609% Z120
18% Z360
2.3 B36021% B36011% B360
6.1 ZB120
7.5 ZB360
47% ZB120 ( ) 60% ZB360 ( )25% ZB120
32% ZB360

RimonabantP-4170.5 (0.3, 1.3)NRNR1.0 (−0.2, 1.9)Psychiatric: 28.4% P, 43.4% R, [98]
R-4224.3 (3.5, 5.1) 4.5 (−3.7, −5.4), Severe psychiatric: 3.5% P, 4.8% R,

Rimonabant3165 (total)Placebo 1.6
R 6.5
19.7%
50.8%,
7.8%
27%,
6.4
2.5
Depression: 0.8% P, 1.9% R, NS Anxiety: 0.3 P, 1.0% R, NS[96]
TesofensinePlacebo-522.2 (0.9, 3.5)13 (29%)3 (7%)−2.4 (0.7, 4.2)Anger and hostility: 4% P, 14.3% T 1 mg, [99]
T 0.25 mg-526.7 (5.4, 8.0), 29 (59%)17 (35%)−5.9 (4.0, 7.8), Increased confusion: P-NA,
T 0.5 mg-5011.3 (9.9, 12.7), 41 (87%)25 (53%)–9·4 (7.7, 11.0), T 0.5 mg ,
T 1.0 mg-4912·8 (11.6, 14.1), 42 (91%)34 (74%)–9·3 (7.6, 11.0), T 1 mg

Absolute weight loss: weight loss from baseline; NS: not significant; NR: not recorded; WC: waist circumference; P: placebo; B: bupropion; N: naltrexone; Z: zonisamide; R: rimonabant; T: tesofensine; NA: not available; pooled non-diabetic patients; #mean ± standard deviation; estimated absolute weight based on mean baseline weight of 100 kg.